Navigation Links
XTL Biopharmaceuticals: AGM/EGM Statements

VALLEY COTTAGE, New York, October 2 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that at its Annual General Meeting and Extraordinary General Meeting held earlier today, all the resolutions proposed to the shareholders were approved.

The cancellation of the listing of the Company's Ordinary Shares on the Official List of the United Kingdom Listing Authority will take place at 8:00 am (London Time) on October 31, 2007.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).


Ron Bentsur

Chief Executive Officer

Tel: +1-845-267-0707 ext. 225

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
(Date:10/12/2015)... , Oct. 12, 2015 This report ... which include cell type, products, applications, end-user markets and ... REPORT HIGHLIGHTS The global cell expansion market generated ... expected to reach revenues of $9.7 billion in 2015 ... growth rate (CAGR) of 17.8% from 2015 to 2020. ...
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, a ... and inflammatory diseases and conditions, today announced the ... stock financing. Concurrent with the close of its ... a Loan and Security Agreement with Silicon Valley ... $7 million. Patara will use the funds from ...
(Date:10/12/2015)... WA (PRWEB) , ... October 12, 2015 , ... NeuMedics ... the treatment of retinal diseases that can safely and chronically be administered as an ... Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to ...
Breaking Biology Technology:
(Date:10/13/2015)... -- Global Next Generation Biometric Market . ... --> Mordor Intelligence is pleased to announce ... Biometric Market . ) --> ... ) --> --> ... increase to $23.8 billion by 2020 at a CAGR ...
(Date:10/12/2015)... NXTD ) ("NXT-ID" or the "Company"), a biometric ... on the recent SNS Future in Review Conference in ... ) ("NXT-ID" or the "Company"), a biometric authentication company focused ... SNS Future in Review Conference in Park City, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
Breaking Biology News(10 mins):